Dinifedriton
 | |
| Clinical data | |
|---|---|
| Other names | HU6 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C11H9N5O7 |
| Molar mass | 323.221 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dinifedriton, also known as HU6, is a prodrug of the mitochondrial uncoupler 2,4-dinitrophenol (DNP) that is intended to "minimize the rapid absorption and high peak blood concentrations of DNP to provide a wider therapeutic index and improve safety."[1] Developed by Rivus Pharmaceuticals, the drug is tested to reduce weight and liver fat in humans with risk factors for metabolic dysfunction-associated steatohepatitis. In a phase 2a trial, the higher dosage levels reduced liver fat on average by more than 30 percent and also reduced body weight significantly.[2][3] A phase 2b trial was launched in late 2023.[4] A phase 2b trial in patients with metabolic dysfunction-associated steatohepatitis was subsequently initiated.[5] Data from this study are expected to be reported in 2025. Additionally, a phase 2a study was performed in patients suffering from heart failure with preserved ejection fraction, a disease that is mediated by visceral fat and obesity. The study achieved the primary endpoint of weight loss, as well as a number of secondary endpoints.[6]
References
[edit]- ↑ Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J (December 2023). "Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial". The Lancet Gastroenterology & Hepatology. 8 (12): 1094–1105. doi:10.1016/S2468-1253(23)00198-X. PMID 37806314.
- ↑ Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). "Clinical Trial Landscape in NASH". Clinical Gastroenterology and Hepatology. 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041. PMID 37059159.
- ↑ Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J (December 2023). "Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial". The Lancet Gastroenterology & Hepatology. 8 (12): 1094–1105. doi:10.1016/S2468-1253(23)00198-X. PMID 37806314.
- ↑ "Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments". Yahoo Finance. 15 November 2023. Retrieved 3 December 2023.
- ↑ "Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments". Yahoo Finance. 15 November 2023. Retrieved 3 December 2023.
- ↑ "Rivus Pharmaceuticals Announces New Clinical Data from Phase 2a HuMAIN Trial Demonstrating Significant Weight Loss with HU6 in Patients with Obesity-Related HeartFailure" (PDF). September 30, 2024.